Journal section: Oral Medicine and Pathology Publication Types: Case Report doi:10.4317/jced.54387 http://dx.doi.org/10.4317/jced.54387

# Hyperpigmentation of hard palate induced by chloroquine therapy

Bruno-Augusto-Benevenuto de Andrade <sup>1</sup>, Nelson-Alejandro Padron-Alvarado <sup>2</sup>, Edgar-Manuel Muñoz-Campos <sup>3</sup>, Thayná-Melo-de Lima Morais <sup>4</sup>, Ricardo Martinez-Pedraza <sup>5</sup>

#### Correspondence:

Department of Oral Diagnosis and Pathology School of Dentistry Federal University of Rio de Janeiro (UFRJ) Av. Professor Rodolpho Paulo Rocco 325, 1º andar – Rio de Janeiro, Brazil 2 brunoabandrade@gmail.com

Received: 06/10/2017 Accepted: 12/11/2017 de Andrade BAB, Padron-Alvarado NA, Muñoz-Campos EM, Morais TML, Martinez-Pedraza R. Hyperpigmentation of hard palate induced by chloroquine therapy. J Clin Exp Dent. 2017;9(12):e1487-91. http://www.medicinaoral.com/odo/volumenes/v9i12/jcedv9i12p1487.pdf

Article Number: 54387 http://www.medicinaoral.com/odo/indice.htm

© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail: jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System

### **Abstract**

The antimalarials are one of the most commonly prescribed drugs for conditions such as lupus erythematosus and rheumatoid arthritis, and the side effects, though infrequent, are well known. The antimalarial agent chloroquine diphosphate usually causes pigmentary changes in the oral mucosa characterized by a bluish-grey to black discolorations mainly in the hard palate. Considering only the hard palate hyperpigmentation caused by chloroquine, to the best of our knowledge, only 13 cases have been reported in the English language literature. We described an additional case of palate hyperpigmentation related to the chronic use of chloroquine diphosphate in a 60-year-old Mexican woman. Although the diagnosis is usually made based on medication history and clinical presentation, a biopsy specimen may be helpful to confirm the diagnosis. Clinicians must be aware of these drugs and their adverse effects in order to make the correct diagnosis and decide on the optimal treatment for the condition.

**Key words:** Oral cavity, hard palate, hyperpigmentation, chloroquine, antimalarials.

### Introduction

Oral mucosal pigmentation is a common finding, usually associated with normal melanin deposition in dark-skinned people. A wide variety of lesions and conditions are associated with abnormal mucosal discoloration. Isolated and well-circumscribed oral pigmented lesions are usually diagnosed as melanotic macule, melanocytic

nevus or amalgam tattoo, or more uncommonly as an initial sign of melanoma. Diffuse or multifocal mucosal hyperpigmentation may be a sign of systemic disease such as Addison's disease, Peutz–Jeghers syndrome, melanoplakia and human immunodeficiency virus (HIV) infection, or a side effect of drug therapy (1-5).

Drugs associated with abnormal oral pigmentation in-

<sup>&</sup>lt;sup>1</sup> DDS, PhD, Oral Pathology, Department of Oral Diagnosis and Pathology, School of Dentistry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

<sup>&</sup>lt;sup>2</sup> DDS, Oral Pathology, Universidad de Carabobo, School of Dentistry, Valencia, Venezuela

<sup>&</sup>lt;sup>3</sup> DDS, Oral Surgery, University of Montemorelos, School of Dentistry, Montemorelos, NL, Mexico

<sup>&</sup>lt;sup>4</sup> DDS, Oral Pathology Section, Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil

<sup>&</sup>lt;sup>5</sup> DDS, Oral Pathology, Universidad Autónoma de Nuevo León, School of Dentistry, Monterrey, NL, Mexico

clude tetracycline, zidovudine, anti-inflammatory drugs and antimalarial agents, such as quinacrine hydrochloride, chloroquine, hydroxychloroquine, and amodiaquine (6). In addition to treating malaria, these medications are used for management of systemic and discoid lupus erythematosus and rheumatoid arthritis (7-18). Clinicians will most likely encounter patients taking these medications and should, therefore, be familiar with this potential oral side effect (1). Early diagnosis of oral pigmentation by antimalarials may be of great relevance. since it might be an early sign of ocular involvement, and therefore it may be helpful to prevent further complications of antimalarial therapy for the patient (1). We describe an additional case of hard palate hyperpigmentation related to the chronic use of chloroquine diphosphate for rheumatoid arthritis treatment.

# **Case Report**

A 60-year-old Mexican woman was referred for evaluation of a diffuse blue-gray pigmentation of the hard palate lasting six months. Her medical history revealed that she had been undergoing treatment with chloroquine diphosphate (150mg/day) for rheumatoid arthritis for 1 year. Clinical examination showed a 4 cm blue-gray pigmented diffuse lesion with irregular borders on the hard palate (Fig. 1). The pigmented area did not blanch



**Fig. 1:** Clinical aspect of hyperpigmentation of hard palate induced by chloroquine therapy showing a blue-gray pigmented diffuse lesion with irregular borders.

with pressure. On extra-oral examination, pigmentation was not seen in the skin or in the ocular conjunctiva. Differential diagnosis included drug-induced hyperpigmentation, Addison's disease, vitamin B12 deficiency, and melanoma. The history of long-term chloroquine use, led to the clinical working diagnosis of drug-induced oral pigmentation caused by chloroquine diphosphate. To confirm this, an incisional biopsy was taken from the hard palate mucosa and sent for histopathological examination.


Microscopical evaluation showed a subepithelial deposition of granular pigment mainly located between co-

llagen fibers and within fibroblasts and macrophages. Staining with Perls' confirmed that the pigment was hemosiderin. Fontana-Masson stain was also positive confirming the presence of melanin (Fig. 2). Immunohistochemistry with CD68 (dilution 1:400, clone PGM-1, Dako, Carpinteria, CA, USA) highlighted macrophages containing intracellular pigment (Fig. 2). These histopathological findings and the clinical appearance of the lesion confirmed the diagnosis of drug-induced oral pigmentation caused by chloroquine diphosphate. The drug was discontinued and the patient was referred for ophthalmologic evaluation that showed no signs of retinopathy.

## **Discussion**

Oral mucosal pigmentation can be result of a wide variety of lesions and conditions. A systematic evaluation, including a complete and accurate patient history and a thorough clinical examination, is essential for the appropriate differential diagnosis (2). Brown, black, or gray discoloration is most often caused by an accumulation of melanin, hemosiderin, or foreign body material, whereas red, blue, or purple color changes suggest a vascular process (2). Multifocal or diffuse distribution of pigmentation suggests a systemic cause, such as a metabolic disorder or drug toxicity. Antimalarial agents, such as chloroquine diphosphate and hydroxychloroquine sulfate, are administered for treatment of several dermatologic and rheumatologic disorders, and they are known to cause hyperpigmentation of the oral mucosa (9,15). Systemic administration of these drugs for a prolonged period is responsible for the appearance of multifocal hyperpigmentation, which is reversible once the medication is discontinued. Oral pigmentation secondary to drug therapy can be attributed to the stimulation of melanin production by melanocytes and/or the deposition of hemosiderin in the tissues (1,2,5).

Lippard and Kauer first described pigmentation of palatal mucosa resulting from antimalarial medication in 1945 (10). Since then, it has been reported by others (1,5,10,11). In most cases, only the hard palate is involved, forming a sharp line of demarcation at the junction of the hard and soft palates (2). An explanation for sparing the soft palate has not been offered. Involvement of gingiva and labial or buccal mucosa has also been reported (4). Considering only the hard palate hyperpigmentation caused by chloroguine, to the best of our knowledge, only 13 cases have been reported in the English language literature (Table 1) (1,3-5,12,16-18). Skin pigmentation can also be observed in patients undergoing treatment with chloroquine diphosphate (2) as well as reversible graying of the scalp hair, beard, eyelashes, and eyebrows (14). Pigmentary changes in the oral mucosa can also be associated with other medicaments including tranquilizers (chlorpromazine), chemotherapeutics (doxorubicin, busulfan, and



**Fig. 2:** Histological aspects of hyperpigmentation of hard palate induced by chloroquine therapy. A – Subepithelial deposition of granular pigment mainly located between collagen fibers and within fibroblasts and macrophages (HE, 400X). B – Staining with Perls' confirmed that the pigment present in the lesion is constituted by hemosiderin (Perls' stain, 400X). C – The pigment deposits were also positive for Fontana-Masson stain (400X). D – Immunohistochemical aspects of hyperpigmentation of hard palate induced by chloroquine therapy. Presence of intracellular dark-brown pigment in the macrophages with CD68 (Permanet red, 400X).

cyclophosphamide), anti-retroviral agents (zidovudine, AZT), antifungal agents ketoconazole), antibiotics (minocycline), and laxatives (phenolphthalein) (13). In the current case, the hyperpigmentation was localized only in the hard patale without cutaneous involvement.

It is important to note that several systemic disorders can promote oral and cutaneous pigmentation and this should be further explored through the medical history. Systemic causes that need to be considered include adrenal insufficiency, Peutz- Jeghers syndrome, hemochromatosis, polyostotic fibrous dysplasia, hyperparathyroidism, and neurofibromatosis (2). Abnormal pigmentation is relatively common in individuals infected with the human immunodeficiency virus (HIV). In some HIV-related cases, pigmentation has been associated with drug therapy or adrenal insufficiency; however, in many cases the cause cannot be identified (15).

The greatest significance of chloroquine-induced hyperpigmentation is the possibility that it may be a marker for a more serious side effect. Irreversible retinopathy which in some cases leads to blindness, is recognized as a potential complication of antimalarial drug therapy and it has been suggested that abnormal skin and mucosal pigmentation may be an indication of ocular involvement (2,3). Based on this potentially severe complication, periodic evaluation is necessary for patients being treated with ongoing antimalarial therapy. Our patient was evaluated by an ophthalmologist showing no signs of retinopathy.

The diagnosis of drug-induced hyperpigmentation is often made based on medication history and clinical presentation. In cases which clinical features are atypical or a complete medication history is not available, a biopsy should be performed to establish the diagnosis (2). Biopsy is particularly important to rule out melanoma, which may initially present as hyperpigmentation of otherwise normal appearing mucosa (2,5).

In chloroquine-induced hyperpigmentation, biopsy specimens of involved mucosa may exhibit gross subepithelial pigmentation (1). Hematoxylin-eosin stained sections demonstrate deposits of granular pigmentation extracellular or within fibroblasts and macrophages scattered throughout the lamina propria. Histochemical stains have been used in an attempt to identify the nature of the pigmentation; however, results have been inconsistent. Authors have identified melanin, hemosiderin, or both (1,5). In our case we confirmed presence of hemosiderin and melanin as the pigment was positive with wither Perls' and Fontana Masson stainings.

For this type of oral pigmentation, no treatment is required. The management involves, if possible, discontinuing the medication or decreasing the dosage, and it has been recommended that these patients also be referred to an ophthalmologist (1,3).

 Table 1: Clinical and microscopical features of 12 cases of hard palate hyperpigmentation induced by chronic chloroquine therapy reported in the English-language literature including the present case.

 Cases
 Authors
 Age/Sex
 Symptoms
 Duration
 Chloroquine
 Dosis
 Color
 Biopsy
 Fontana
 Peris'
 Retinopathy
 Skin

Zachariae, 1963 (12)         47/F         Painless         NR         NR         250mg         Dark         No         NR         NR           Bentsi-Enchill, 1980 (16)         44/F         Painless         NR         6 years         NR         Grayish         No         NR         NR           Gallo et al., 2010 (4)         66/F         Painless         3 months         3 years         NR         Blue-gray         Yes         NR         NR           Moraes et al., 2011 (4)         66/F         Painless         NR         10 years         250mg         Blue-gray         Yes         NR         NR           de Melo Filho et al., 2012 (5)         60/F         Painless         3 months         15 years         250mg         Blue-gray         Yes         Negative         Positive           Brasil et al., 2012 (5)         60/F         Painless         1 month         3 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         1 years         250mg         Blue-gray         Yes         Negative         Positive           60/M         Painless         NR         3 years         250mg         Blue-gray	Cases	Authors	Age/Sex	Symptoms	Duration	Chloroquine therapy time	Dosis (day)	Color	Biopsy	Fontana Masson	Perls'	Retinopathy	Skin hyperpigmentation
Bentsi-Enchill, 1980 (16)         44/F         Painless         NR         6 years         NR         Blue-gray         Yes         NR         NR           Gallo et al., 2009 (3)         65/F         Painless         3 months         3 years         NR         Blue-gray         Yes         NR         NR           Moraes et al., 2011 (4)         66/F         Painless         NR         10 years         250mg         Blue-gray         Yes         NR         NR           de Meto Filho et al., 2012 (5)         66/F         Painless         3 months         15 years         200mg         Blue-gray         Yes         NR         NR           de Adracte et al., 2012 (5)         60/F         Painless         1 month         3 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         10 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         12 years         250mg         Blue-gray         Yes         Negative         Positive           66/M         Painless         NR         12 years         250mg	1	Zachariae, 1963 (12)	47/F	Painless	NR	NR	250mg	Dark	No	NR	NR	No	Yes
Gallo et al., 2009 (3)         65/F         Painless         3 months         3 years         NR         Blue-gray         Yes         NR         NR           Moraes et al., 2011 (4)         66/F         Painless         NR         10 years         NR         Blue-gray         Yes         NR         NR           de Melo Filho et al., 2012 (5)         64/F         Painless         3 months         15 years         200mg         Burk         Yes         Positive         NR           de Andrade et al., 2012 (5)         60/F         Painless         1 month         3 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         10 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         59/M         Painless         NR         10 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless         NR         12 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless         N	2	Bentsi-Enchill, 1980 (16)	44/F	Painless	NR	6 years	NR	Grayish	No	NR	NR	Yes	Yes
Moraes et al., 2011 (4)         66/F         Painless         NR         10 years         NR         Blue-gray         Yes         NR         NR           de Melo Filho et al., 2012 (5)         66/F         Painless         3 months         15 years         250mg         Blue-gray         Yes         Positive         NR           de Andrade et al., 2012 (5)         60/F         Painless         1 month         3 years         4 mg/kg         Dark-blue         Yes         NR         NR           de Andrade et al., 2013 (1)         54/F         Painless         NR         4 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         10 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2017 (18)         65/F         Painless         NR         12 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless         NR         4 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless	3-4	Gallo et al., 2009 (3)	65/F	Painless		3 years	NR	Blue-gray	Yes	NR	NR	No	Yes
Moraes et al., 2011 (4)         66/F         Painless         NR         NR         250mg         Blue-gray         Yes         Positive         Negative           de Melo Filho         (17)         64/F         Painless         3 months         15 years         200mg         Dark-blue         Yes         NR         NR           de Andrade et al., 2012 (5)         60/F         Painless         1 month         3 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         10 years         250mg         Blue-gray         Yes         Negative         Positive           de Andrade et al., 2017 (18)         60/M         Painless         NR         12 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless         NR         4 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless         NR         4 years         250mg         Blue-gray         Yes         Negative         Positive			71/F	Painless	NR	10 years	NR	Blue-gray	Yes	NR	NR	No	Yes
de Melo Filho et al., 2012         64/F         Painless         3 months         15 years         200mg         Dark per         Yes         NR         NR           Brasil et al., 2013 (1)         54/F         Painless         1 month         3 years         4mg/kg         Dark-blue         Yes         Negative         Positive           de Andrade et al., 2013 (1)         54/F         Painless         NR         4 years         250mg         Blue-gray         Yes         Negative         Positive           59/M         Painless         NR         12 years         250mg         Dark-gray         Yes         Negative         Positive           60/M         Painless         NR         12 years         250mg         Blue-gray         Yes         Negative         Positive           Manger et al., 2017 (18)         50/F         Painless         NR         4 years         250mg         Blue-gray         Yes         Negative         Positive           Present case         60/F         Painless         NR         4 years         250mg         Bluish-gray         Yes         Negative         Positive	S	Moraes et al., 2011 (4)	4/99	Painless	NR	NR	250mg	Blue-gray	Yes	Positive	Negative	No	No
Brasil et al., 2012 (5)       60/F       Painless       1 month       3 years       4mg/kg       Dark-blue       Yes       Negative       Positive         de Andrade et al., 2013 (1)       54/F       Painless       NR       10 years       250mg       Blue-gray       Yes       Negative       Positive         83/F       Painless       NR       12 years       250mg       Dark-gray       Yes       Negative       Positive         60/M       Painless       NR       12 years       250mg       Blue-gray       Yes       Negative       Positive         Manger et al., 2017 (18)       50/F       Painless       NR       4 years       250mg       Bluish-grey       Yes       Negative       Positive         Present case       60/F       Painless       NR       4 years       250mg       Bluish-grey       Yes       Negative       Positive	9	de Melo Filho <i>et al.</i> , 2012 (17)	64/F	Painless		15 years	200mg	Dark	Yes	NR	NR	Yes	No
de Andrade et al., 2013 (1) 54/F Painless NR 10 years 250mg Blue-gray Yes Negative Positive Positive S9/M Painless NR 3 years 250mg Dark-gray Yes Negative Positive Positive G0/M Painless NR 12 years 250mg Blue-gray Yes Negative Positive Positive Ananger et al., 2017 (18) 50/F Painless NR 4 years 250mg Bluish-grey Yes Negative Positive Positive Positive Positive Positive Present case 60/F Painless 6 months 1 year 150mg Blue-gray Yes Positive	7	Brasil et al., 2012 (5)	4/09	Painless	1 month	3 years	4mg/kg	Dark-blue	Yes	Negative	Positive	No	No
Manger et al., 2017 (18)       59/M       Painless       NR       10 years       250mg       Blue-gray       Yes       Negative       Positive         Manger et al., 2017 (18)       60/M       Painless       NR       12 years       250mg       Blue-gray       Yes       Negative       Positive         Manger et al., 2017 (18)       50/F       Painless       NR       4 years       250mg       Bluish-gray       Yes       NR       Positive         Present case       60/F       Painless       6 months       1 year       150mg       Blue-gray       Yes       Positive       Positive	8-12	de Andrade et al., 2013 (1)	54/F	Painless	NR	4 years	250mg	Blue-gray	Yes	Negative	Positive	No	No
Manger et al., 2017 (18) 50/F Painless 6 months Present case 60/F Painless 6 months 1 years 250mg Blue-gray Yes Rogative Positive Positive Present case 60/F Painless 6 months 1 years 250mg Blue-gray Yes Rogative Positive Positiv			M/65	Painless	NR	10 years	250mg	Blue-gray	Yes	Negative	Positive	No	No
Manger et al., 2017 (18) 50/F Painless NR 1 years 250mg Blue-gray Yes Negative Positive Manger et al., 2017 (18) 50/F Painless NR 4 years 250mg Bluish-grey Yes NR Positive Positive Present case 60/F Painless 6 months 1 year 150mg Blue-gray Yes Positive Positive			83/F	Painless	NR	3 years	250mg	Dark-gray	Yes	Negative	Positive	No	No
Manger et al., 2017 (18) 50/F Painless NR 4 years 250mg Blue-gray Yes Negative Positive  Present case 60/F Painless 6 months 1 year 150mg Blue-gray Yes Positive Positive			W/09	Painless	NR	12 years	250mg	Dark	Yes	Negative	Positive	No	No
Manger et al., 2017 (18)50/FPainlessNR4 years250mgBluish-greyYesNRPositivePresent case60/FPainless6 months1 year150mgBlue-grayYesPositivePositive			65/F	Painless	NR	3 years	250mg	Blue-gray	Yes	Negative	Positive	No	No
Present case 60/F Painless 6 months 1 year 150mg Blue-gray Yes Positive Positive	13	Manger et al., 2017 (18)	50/F	Painless	NR	4 years	250mg	Bluish-grey	Yes	NR	Positive	No	No
	14	Present case	4/09	Painless		1 year	150mg	Blue-gray	Yes	Positive	Positive	No	No

F: Female; M: Male, NR: not reported.

In summary, diffuse oral pigmentation can be a sign of drug side effect and should be included as part of the clinical differential diagnosis of hyperpigmentation of the oral mucosa. Antimalarial agents such as chloroquine are among the drugs more commonly associated with this mucosal alteration. Although the diagnosis is usually made based on medication history and clinical presentation, a biopsy specimen may be helpful to confirm the diagnosis. The management involves discontinuing or decreasing use of the drug and referral for ophthalmologic examination.

### References

- 1. de Andrade BA, Fonseca FP, Pires FR, Mesquita AT, Falci SG, Dos Santos Silva AR, et al. Hard palate hyperpigmentation secondary to chronic chloroquine therapy: report of five cases. J Cutan Pathol. 2013;40:833-8.
- 2. Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:189-94.
- 3. Gallo CB, Luiz AC, Ferrazzo KL, Migliari DA, Sugaya NN. Drug-induced pigmentation of hard palate and skin due to chronic chloroquine therapy: report of two cases. Clin Exp Dermatol. 2009;34:e266-7.
- 4. Moraes PC, Noce CW, Thomaz LA, Cintra ML, Correa ME. Pigmented lichenoid drug eruption secondary to chloroquine therapy: an unusual presentation in lower lip. Minerva Stomatol. 2011;60:327-32.
- 5. Brasil Cda M, Ribeiro CM, Fonseca DD, Gueiros LA, Leao JC. Chloroquine-induced hyperpigmentation of the hard palate. Gen Dent. 2012;60:e74-8.
- 6. Kauzman A, Pavone M, Blanas N, Bradley G. Pigmented lesions of the oral cavity: review, differential diagnosis, and case presentations. J Can Dent Assoc. 2004;70:682-3.
- 7. Wozniacka A, McCauliffe DP. Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol. 2005;6:1-11.
- 8. Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol. 2000;18:525-32.
- 9. Lerman MA, Karimbux N, Guze KA, Woo SB. Pigmentation of the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:8-12.
- 10. Lippard VW, Kauer GL Jr. Pigmentation of the palate and subungual tissues associated with suppressive quinacrine hydrochloride therapy. Am J Trop Med Hyg. 1945;25:469-71.
- 11. Giansanti JS, Tillery DE, Olansky S. Oral mucosal pigmentation resulting from antimalarial therapy. Oral Surg Oral Med Oral Pathol. 1971;31:66-9.
- 12. Zachariae H. Pigmentation of skin and oral mucosa after prolonged treatment with chloroquine. Acta Derm Venereol. 1963;43:149-53.
- 13. Seymour RA, Rudralingham M. Oral and dental adverse drug reactions. Periodontol 2000.2008;46:9-26.
- 14. Koranda FC. Antimalarials. J Am Acad Dermatol. 1981;4:650-5.
- 15. Porter SR, Glover S, Scully C. Oral hyperpigmentation and adrenocortical hypofunction in a patient with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol. 1990;70:59-60.
- 16. Bentsi-Enchill KO. Pigmentary skin changes associated with ocular chloroquine toxicity in Ghana. Trop Geogr Med. 1980;32:216-20.
- 17. de Melo Filho MR, da Silva CA, da Rocha Dourado M, de Oliveira Pires MB, Pêgo SP, de Freitas EM. Palate hyperpigmentation caused by prolonged use of the anti-malarial chloroquine. Head Neck Pathol. 2012;6:48-50.
- 18. Manger K, von Streitberg U, Seitz G, Kleyer A, Manger B. Hard palate yperpigmentation a rare side effect of antimalarials. Arthritis Rheumatol.2017 Sep 21.

#### **Conflict of Interest**

The authors declare that they have no conflict of interest.